Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 2, 2009

Novasep Purchases Henogen for Upstream Processing Capabilities

  • Novasep is acquiring Henogen thus adding a range of upstream processing capabilities and services to its downstream processing (DSP) offerings. Novasep reports that with this acquisition it will be able to offer a complete manufacturing solution for antibody-drug conjugates, covering early development to future commercial production.

    Henogen has more than 100 employees and operates two biomanufacturing facilities south of Brussels. It will become a part of Novasep Process, the biomolecules division. Henogen brings experience with an extensive array of expression tools including E. coli, yeast, L. lactis, insect and mammalian cells, as well as viral vectors.

    The two companies have previously cooperated on biomanufacturing projects. Combined services to be offered with this takeover now include upstream and downstream processing, contract biomanufacturing services, as well as chromatography and membrane-filtration technologies.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »